- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease
A professional analysis of the potential cost-effective impact of emerging dry eye therapies on the health care system.
EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments
EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease
EP: 3.Navigating Different Subtypes of Dry Eye Disease
EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes
EP: 5.Updating Formularies: Considerations for Dry Eye Disease
EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease
EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease
EP: 8.Resource Allocation in the Treatment of Dry Eye Disease
EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease
EP: 10.Annual Health Care Costs of Managing Dry Eye Disease
EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease
EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease
EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease
EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Haumschild queries cost-effectiveness considerations around emerging dry eye disease (DED) therapies. Parekh states early DED identification and tailored treatment represents prevention, optimizing societal outcomes over following thousands of patients. Applying this population health approach can modify disease trajectory. Delaying intervention risks irreversible ocular surface damage and vision impairment despite eventual treatment. An upfront focus on appropriate therapy facilitates quality outcomes in a value-based model.
Kabiri discusses the responsibility for providers to address DED’s high prevalence with patient education and evidence-based recommendations, not just reacting to active complaints. Patients increasingly self-diagnose DED and expect specialist guidance on best practices. Effectively communicating around promising therapies enables access that impacts countless patients. Haumschild concurs this represents both an obligation and opportunity for optimal DED management benefiting all stakeholders.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Collaborative Care Model Offers Success in Reducing Suicide Risk, New Report Finds
April 10th 2025A report published today by the American Foundation for Suicide Prevention underscores the potential of the collaborative care model to lower suicide risk across diverse patient populations and health systems.
Read More
Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer
April 9th 2025Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Read More
Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD
April 8th 2025The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
